LRWD1 Knockout cell line (JAR)

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

LRWD1 (leucine rich repeats and WD repeat domain containing 1) encodes a protein that interacts with the origin recognition complex and contributes to the formation of prereplication complexes. LRWD1 supports DNA replication by stabilizing components of the replication initiation machinery and is required for the G1/S cell cycle transition. It also associates with heterochromatin and contributes to the recruitment of factors involved in maintaining repressive chromatin states.

JAR is a human choriocarcinoma cell line established from a trophoblastic tumor of the placenta of a 24-year-old woman. The cell line originates from a male fetus and represents a trophoblast-derived tumor model. JAR is used for studies of placental biology, trophoblast differentiation, and mechanisms involved in gestational cancers.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.